Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Goodwill & Intangibles (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Goodwill & Intangibles data on record, last reported at $42.4 million in Q4 2025.

  • For Q4 2025, Goodwill & Intangibles rose 297.04% year-over-year to $42.4 million; the TTM value through Dec 2025 reached $42.4 million, up 297.04%, while the annual FY2025 figure was $42.4 million, 297.04% up from the prior year.
  • Goodwill & Intangibles reached $42.4 million in Q4 2025 per LCTX's latest filing, up from $10.7 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $76.8 million in Q4 2022 and bottomed at $10.7 million in Q3 2021.
  • Average Goodwill & Intangibles over 5 years is $28.1 million, with a median of $10.7 million recorded in 2021.
  • Peak YoY movement for Goodwill & Intangibles: tumbled 86.11% in 2021, then soared 437.21% in 2023.
  • A 5-year view of Goodwill & Intangibles shows it stood at $10.7 million in 2021, then surged by 619.78% to $76.8 million in 2022, then crashed by 86.08% to $10.7 million in 2023, then fell by 0.21% to $10.7 million in 2024, then surged by 297.04% to $42.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Goodwill & Intangibles were $42.4 million in Q4 2025, $10.7 million in Q3 2025, and $42.4 million in Q2 2025.